SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Richard F. Potthoff, Susan Halabi, A novel test to compare two treatments based on endpoints involving both nonfatal and fatal events, Pharmaceutical Statistics, 2015, 14, 2
  2. 2
    K. R. Johnson, W. Liauw, M. N. D. Lassere, Evaluating surrogacy metrics and investigating approval decisions of progression-free survival (PFS) in metastatic renal cell cancer: a systematic review, Annals of Oncology, 2015, 26, 3, 485

    CrossRef

  3. 3
    Emilio Bria, Francesco Massari, Francesca Maines, Sara Pilotto, Maria Bonomi, Camillo Porta, Sergio Bracarda, Daniel Heng, Daniele Santini, Isabella Sperduti, Diana Giannarelli, Francesco Cognetti, Giampaolo Tortora, Michele Milella, Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysis, Critical Reviews in Oncology/Hematology, 2015, 93, 1, 50

    CrossRef

  4. 4
    Susan Halabi, Brian I. Rini, Bernard Escudier, Walter M. Stadler, Eric J. Small, Progression-free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?, Cancer, 2015, 121, 10
  5. 5
    Andreas Becker, Christian Eichelberg, Maxine Sun, Reply to progression-free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?, Cancer, 2015, 121, 10
  6. 6
    Gillian M. Keating, Bevacizumab: A Review of Its Use in Advanced Cancer, Drugs, 2014, 74, 16, 1891

    CrossRef

  7. 7
    Antoine Thiery-Vuillemin, Christine Theodore, Lutz Jacobasch, Jörg Schmitz, Christos Papandreou, Aline Guillot, Christos Emmanouilides, Khemaies Slimane, Nadia Kelkouli, Stefano Kim, Thierry Nguyen Tan Hon, Efficacy and Safety of Sequential Use of Everolimus in Patients With Metastatic Renal Cell Carcinoma Previously Treated With Bevacizumab With or Without Interferon Therapy: Results From the European AVATOR Study, Clinical Genitourinary Cancer, 2014,

    CrossRef

  8. 8
    Peter Leiner, Nierenzellkarzinom: Reicht progressionsfreies Überleben als Erfolgskriterium in Studien aus?, Uro-News, 2014, 18, 2, 43

    CrossRef

  9. 9
    Andreas Becker, Christian Eichelberg, Maxine Sun, Progression-free survival: Does a correlation with survival justify its role as a surrogate clinical endpoint?, Cancer, 2014, 120, 1
  10. 10
    René Adam, Surrogate Markers of Overall Survival in Metastatic Colorectal Cancer: An Evolving Challenge Still More Complex with Repeat Surgery, Annals of Surgical Oncology, 2014, 21, 6, 1763

    CrossRef